Alcidion Group Limited (AU:ALC)
ASX:ALC
Top Page
Alcidion Group Limited
(Sydney:ALC)
Select Model
Select Model
Rating:67Neutral
Price Target:
AU$0.11
▲(9.00% Upside)
Action:ReiteratedDate:01/22/26
The score is driven mainly by improving financial performance (strong revenue growth, very low leverage, and sharply better cash generation) and supportive technical trend signals (price above key moving averages with positive MACD). These positives are moderated by an expensive valuation (P/E 108.33) and still-weak operating profitability (negative EBIT margin and low net margin).
Positive Factors
Revenue Growth
Consistent mid-teens revenue growth reflects expanding adoption of Alcidion's clinical software across hospitals and health systems. Over a 2–6 month horizon this trend supports recurring subscription revenue, potential contract expansions, and scale benefits that can strengthen long-term customer retention and upsell opportunities.
Negative Factors
Negative EBIT Margin
Despite strong gross margins, a negative EBIT margin shows core operating costs still exceed operating income. Unless management reduces SG&A or achieves scale efficiencies, ongoing negative EBIT could persist, limiting sustainable operating profitability and constraining reinvestment capacity over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent mid-teens revenue growth reflects expanding adoption of Alcidion's clinical software across hospitals and health systems. Over a 2–6 month horizon this trend supports recurring subscription revenue, potential contract expansions, and scale benefits that can strengthen long-term customer retention and upsell opportunities.
Read all positive factors
Alcidion Group Limited (ALC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$134.30M
Dividend YieldN/A
Average Volume (3M)796.98K
Price to Earnings (P/E)26.5
Beta (1Y)1.13
Revenue Growth10.06%
EPS GrowthN/A
CountryAU
Employees145
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,342,952,600
10 Day Avg. Volume536,053
30 Day Avg. Volume796,979
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)1.57
Price to Sales (P/S)3.38
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.14Price Target Upside40.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$51.40M
Alcidion Group Limited Business Overview & Revenue Model
Company Description
Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare i...
How the Company Makes Money
Alcidion makes money by selling, implementing, and supporting its healthcare software products for hospitals and health systems. Key revenue streams include: (1) Software licensing / subscriptions: recurring fees for access to its software (includ...
Alcidion Group Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
78
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 48.62M | 40.79M | 37.06M | 40.40M | 34.35M | 25.88M |
| Gross Profit | 25.73M | 35.99M | 31.92M | 1.25M | 3.29M | 3.52M |
| EBITDA | 7.27M | 1.94M | -4.50M | -1.43M | -1.58M | -474.00K |
| Net Income | 3.87M | 1.65M | -8.42M | -3.62M | -4.41M | -2.24M |
Balance Sheet | ||||||
| Total Assets | 118.08M | 115.63M | 114.46M | 120.68M | 128.35M | 58.38M |
| Cash, Cash Equivalents and Short-Term Investments | 14.20M | 17.70M | 11.80M | 14.64M | 17.34M | 25.03M |
| Total Debt | 1.32M | 1.41M | 1.70M | 2.15M | 2.48M | 181.00K |
| Total Liabilities | 28.45M | 27.82M | 27.52M | 30.52M | 34.40M | 13.16M |
| Stockholders Equity | 89.64M | 87.80M | 86.94M | 90.17M | 93.95M | 45.22M |
Cash Flow | ||||||
| Free Cash Flow | 7.17M | 5.64M | -7.18M | -285.00K | 685.00K | 1.23M |
| Operating Cash Flow | 7.32M | 5.76M | -7.13M | 169.00K | 996.00K | 1.54M |
| Investing Cash Flow | -147.00K | -125.00K | -53.00K | -3.14M | -59.74M | -9.84M |
| Financing Cash Flow | -789.00K | -764.00K | 4.34M | -616.00K | 51.33M | 17.23M |
Alcidion Group Limited Technical Analysis
Negative
0.10
Price Trends
0.11
Negative
0.10
Negative
0.10
Negative
Market Momentum
>-0.01
Negative
44.70
Neutral
28.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ALC.
Alcidion Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$134.30M | 26.51 | 4.37% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$141.94M | -13.72 | -226.75% | ― | 21.56% | -24.08% | |
47 Neutral | AU$61.10M | -6.28 | -23.86% | ― | 15.99% | 22.05% | |
44 Neutral | AU$40.69M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$66.29M | -6.64 | -59.96% | ― | ― | ― | |
42 Neutral | AU$40.76M | -3.13 | -1009.84% | ― | 25.98% | 22.10% |
* Healthcare Sector Average
AU:ALC
Alcidion Group Limited
0.10
0.02
25.00%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.19
-0.11
-38.33%
AU:M7T
Mach7 Technologies
0.26
-0.08
-23.53%
AU:BMT
Beamtree Holdings Ltd
0.14
-0.10
-41.67%
AU:SHG
Singular Health Group Ltd
0.21
-0.02
-10.64%
AU:PCK
PainChek Ltd
0.20
-0.15
-44.29%
Alcidion Group Limited Corporate Events
Alcidion frames H1 FY26 results with strong caveats on non‑IFRS data and investor reliance
Feb 25, 2026
Alcidion Group Limited has released its H1 FY26 results presentation, outlining financial information prepared in accordance with Australian accounting standards and noting that all figures are presented in Australian dollars. The company emphasis...
Alcidion posts record H1 FY26 as recurring revenue and flagship contracts drive growth
Feb 25, 2026
Alcidion reported its strongest half-year performance for H1 FY26, with revenue rising 44% to $25.5 million and underlying EBITDA jumping 675% to $4.2 million, supported by balanced contributions from the UK and ANZ markets. Annual recurring reven...
Alcidion swings to profit on 44% surge in half-year revenue
Feb 25, 2026
Alcidion Group Limited reported a sharp improvement in its half-year financial performance to 31 December 2025, driven by strong revenue growth from recent contract wins and previously signed deals reaching full run-rate. Revenue from ordinary act...
Alcidion Expands Contract Pipeline and Reaffirms Guidance on Strong Q2 Momentum
Jan 14, 2026
Alcidion reported solid momentum in the December quarter of FY26, highlighted by its selection as preferred supplier for a major Electronic Patient Record contract with University Hospitals Sussex NHS Foundation Trust, expected to carry a total co...
Alcidion Schedules Q2 FY26 Cash Flow Release and Investor Webcast
Jan 8, 2026
Alcidion Group Limited will release its Appendix 4C Quarterly Cash Flow Report for the quarter ended 31 December 2025 (Q2 FY26) on 15 January 2026 and will host a live investor webcast the same day, led by Group Managing Director and CEO Kate Quir...
Alcidion Named Preferred EPR Supplier for Major UK NHS Trust
Jan 7, 2026
Alcidion Group has been selected as the preferred supplier of a new Electronic Patient Record (EPR) system for University Hospitals Sussex NHS Foundation Trust in the UK, following a competitive tender process. The trust, one of the country’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.